{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:29:54Z","timestamp":1780410594806,"version":"3.54.1"},"reference-count":60,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"unspecified","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish government","award":["ALFGBG-965885"],"award-info":[{"award-number":["ALFGBG-965885"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["(2021-06545)"],"award-info":[{"award-number":["(2021-06545)"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,2]]},"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In order to enable long-term follow-up of the natural course of HIV infection in the central nervous system, a longitudinal cohort study with repeated cerebrospinal fluid (CSF) analyses at intervals over time was initiated in 1985. When antiretrovirals against HIV were introduced in the late 1980s, short-term and long-term effects of various antiretroviral treatment (ART) regimens were added to the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All adult people living with HIV (PLWH) who were diagnosed at or referred to the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were asked to participate in the Gothenburg HIV CSF Study Cohort. PLWH with neurological symptoms or other clinical symptoms of HIV, as well as those with no symptoms of HIV infection, were included. Most participants were asymptomatic, which distinguishes this cohort from most other international HIV CSF studies. In addition, HIV-negative controls were recruited. These included people on HIV pre-exposure prophylaxis who served as lifestyle-matched controls to HIV-infected men who have sex with men. Since lumbar puncture (LP) is an invasive procedure, some PLHW only consented to participate in one examination. Furthermore, at the beginning of the study, several participants were lost to follow-up having died from AIDS. Of 662 PLWH where an initial LP was done, 415 agreed to continue with follow-up. Among the 415, 56 only gave permission to be followed with LP for less than 1\u2009year, mainly to analyse the short-term effect of ART. The remaining 359 PLWH were followed up with repeated LP for periods ranging from &gt;1\u2009to 30 years. This group was defined as the \u2018longitudinal cohort\u2019. So far, on 7 April 2022, 2650 LP and samplings of paired CSF\/blood had been performed, providing a unique biobank.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>A general finding during the 37-year study period was that HIV infection in the central nervous system, as mirrored by CSF findings, appears early in the infectious course of the disease and progresses slowly in the vast majority of untreated PLWH. Combination ART has been highly effective in reducing CSF viral counts, inflammation and markers of neural damage. Minor CSF signs of long-term sequels or residual inflammatory activity and CSF escape (viral CSF blips) have been observed during follow-up. The future course of these changes and their clinical impact require further studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>PLWH today have a life expectancy close to that of non-infected people. Therefore, our cohort provides a unique opportunity to study the long-term effects of HIV infection in the central nervous system and the impact of ART and is an ongoing study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-070693","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:00:49Z","timestamp":1684321249000},"page":"e070693","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid \u2013 the Gothenburg HIV CSF Study Cohort"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5685-297X","authenticated-orcid":false,"given":"Lars","family":"Hagberg","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"2025120518530504000_13.5.e070693.1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199907090-00015"},{"key":"2025120518530504000_13.5.e070693.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70165-4"},{"key":"2025120518530504000_13.5.e070693.3","doi-asserted-by":"publisher","DOI":"10.3109\/00365548609021668"},{"key":"2025120518530504000_13.5.e070693.4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(86)92699-1","article-title":"Isolation of human immunodeficiency virus from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms","volume":"2","author":"Chiodi","year":"1986","journal-title":"Lancet"},{"key":"2025120518530504000_13.5.e070693.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1992.tb05082.x"},{"key":"2025120518530504000_13.5.e070693.6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1034\/j.1600-0404.2000.102003169.x","article-title":"Slowed reaction time in HIV-1-infected patients without AIDS","volume":"102","author":"Mellgren","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"2025120518530504000_13.5.e070693.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.acn.2005.07.011"},{"key":"2025120518530504000_13.5.e070693.8","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acp010"},{"key":"2025120518530504000_13.5.e070693.9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1080\/23744235.2019.1670352","article-title":"Switching from a regimen containing abacavir\/lamivudine or emtricitabine\/tenofovir disoproxil fumarate to emtricitabine\/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection","volume":"51","author":"Yilmaz","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2025120518530504000_13.5.e070693.10","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1128\/jcm.30.7.1768-1771.1992","article-title":"Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals","volume":"30","author":"Chiodi","year":"1992","journal-title":"J Clin Microbiol"},{"key":"2025120518530504000_13.5.e070693.11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00042560-199804010-00001","article-title":"Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study","volume":"17","author":"Gissl\u00e9n","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2025120518530504000_13.5.e070693.12","first-page":"114","article-title":"Hiv-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir","volume":"12","author":"Gissl\u00e9n","year":"1998","journal-title":"AIDS"},{"key":"2025120518530504000_13.5.e070693.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0481-8"},{"key":"2025120518530504000_13.5.e070693.14","doi-asserted-by":"publisher","DOI":"10.1086\/523648"},{"key":"2025120518530504000_13.5.e070693.15","doi-asserted-by":"publisher","DOI":"10.1007\/BF01646922"},{"key":"2025120518530504000_13.5.e070693.16","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001950"},{"key":"2025120518530504000_13.5.e070693.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088591","article-title":"Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients","volume":"9","author":"Jessen Krut","year":"2014","journal-title":"PLoS One"},{"key":"2025120518530504000_13.5.e070693.18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/1096-9071(200009)62:1<9::AID-JMV2>3.0.CO;2-D","article-title":"Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation","volume":"62","author":"Andersson","year":"2000","journal-title":"J Med Virol"},{"key":"2025120518530504000_13.5.e070693.19","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-199908010-00003"},{"key":"2025120518530504000_13.5.e070693.20","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-5-98","article-title":"Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment","volume":"5","author":"Spudich","year":"2005","journal-title":"BMC Infect Dis"},{"key":"2025120518530504000_13.5.e070693.21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/cid\/ciab943","article-title":"Cerebrospinal fluid viral load across the spectrum of untreated human immunodeficiency virus type 1 (HIV-1) infection: a cross-sectional multicenter study","volume":"75","author":"Ulfhammer","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025120518530504000_13.5.e070693.22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3109\/00365549409011810","article-title":"Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study","volume":"26","author":"Gissl\u00e9n","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"2025120518530504000_13.5.e070693.23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01710672","article-title":"Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment","volume":"20","author":"Hagberg","year":"1992","journal-title":"Infection"},{"key":"2025120518530504000_13.5.e070693.24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/00365549609037914","article-title":"Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine","volume":"28","author":"Hagberg","year":"1996","journal-title":"Scand J Infect Dis"},{"key":"2025120518530504000_13.5.e070693.25","doi-asserted-by":"crossref","DOI":"10.1016\/0140-6736(93)92724-8","article-title":"Zidovudine-Resistant variants of HIV-1 in brain","volume":"342","author":"Di Stefano","year":"1993","journal-title":"Lancet"},{"key":"2025120518530504000_13.5.e070693.26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/135965350601100707","article-title":"Cerebrospinal fluid viral loads reach less than 2 copies\/ml in HIV-1-infected patients with effective antiretroviral therapy","volume":"11","author":"Yilmaz","year":"2006","journal-title":"Antivir Ther"},{"key":"2025120518530504000_13.5.e070693.27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0140-6736(05)60498-9","article-title":"Neurological efficacy of stavudine, zidovudine, and lamivudine","volume":"352","author":"Gissl\u00e9n","year":"1998","journal-title":"Lancet"},{"key":"2025120518530504000_13.5.e070693.28","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000277635.05973.55"},{"key":"2025120518530504000_13.5.e070693.29","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410025320"},{"key":"2025120518530504000_13.5.e070693.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00281.x"},{"key":"2025120518530504000_13.5.e070693.31","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-021-02527-8","article-title":"Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection","volume":"21","author":"Anesten","year":"2021","journal-title":"BMC Neurol"},{"key":"2025120518530504000_13.5.e070693.32","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2017.1341313"},{"key":"2025120518530504000_13.5.e070693.33","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-10-62","article-title":"Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy","volume":"10","author":"Yilmaz","year":"2013","journal-title":"J Neuroinflammation"},{"key":"2025120518530504000_13.5.e070693.34","doi-asserted-by":"publisher","DOI":"10.1086\/657342"},{"key":"2025120518530504000_13.5.e070693.35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw454"},{"key":"2025120518530504000_13.5.e070693.36","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000400"},{"key":"2025120518530504000_13.5.e070693.37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903107106"},{"key":"2025120518530504000_13.5.e070693.38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir667"},{"key":"2025120518530504000_13.5.e070693.39","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181f5b3d1"},{"key":"2025120518530504000_13.5.e070693.40","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/infdis\/jiz030","article-title":"Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma","volume":"220","author":"Hellmuth","year":"2019","journal-title":"J Infect Dis"},{"key":"2025120518530504000_13.5.e070693.41","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/infdis\/jiz031","article-title":"Antiretroviral treatment of acute HIV infection normalizes levels of cerebrospinal fluid markers of central nervous system (CNS) inflammation: a consequence of a reduced CNS reservoir?","volume":"220","author":"Gissl\u00e9n","year":"2019","journal-title":"J Infect Dis"},{"issue":"Suppl 2","key":"2025120518530504000_13.5.e070693.42","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw275","article-title":"Immunologic biomarkers, morbidity, and mortality in treated HIV infection","volume":"214 Suppl 2","author":"Hunt","year":"2016","journal-title":"J Infect Dis"},{"key":"2025120518530504000_13.5.e070693.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160192","article-title":"Anti-Hiv antibody responses and the HIV reservoir size during antiretroviral therapy","volume":"11","author":"Lee","year":"2016","journal-title":"PLoS ONE"},{"key":"2025120518530504000_13.5.e070693.44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix662"},{"key":"2025120518530504000_13.5.e070693.45","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-015-0265-9"},{"key":"2025120518530504000_13.5.e070693.46","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/cid\/ciy1066","article-title":"Human immunodeficiency virus type 1 RNA detected in the central nervous system (CNS) after years of suppressive antiretroviral therapy can originate from a replicating CNS reservoir or clonally expanded cells","volume":"69","author":"Joseph","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025120518530504000_13.5.e070693.47","doi-asserted-by":"publisher","DOI":"10.1080\/003655400750044926"},{"key":"2025120518530504000_13.5.e070693.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250987","article-title":"Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression","volume":"16","author":"Gisslen","year":"2021","journal-title":"PLoS ONE"},{"key":"2025120518530504000_13.5.e070693.49","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002063"},{"key":"2025120518530504000_13.5.e070693.50","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx108","article-title":"High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid","volume":"4","author":"Booiman","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2025120518530504000_13.5.e070693.51","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/QAD.0000000000002980","article-title":"Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis","volume":"35","author":"Robertson","year":"2021","journal-title":"AIDS"},{"key":"2025120518530504000_13.5.e070693.52","doi-asserted-by":"publisher","DOI":"10.1086\/650538"},{"key":"2025120518530504000_13.5.e070693.53","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328355e6b2"},{"key":"2025120518530504000_13.5.e070693.54","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-015-0267-7"},{"key":"2025120518530504000_13.5.e070693.55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236162","article-title":"Herpes zoster in HIV-1 infection: the role of CSF pleocytosis in secondary CSF escape and discordance","volume":"15","author":"Hagberg","year":"2020","journal-title":"PLoS ONE"},{"key":"2025120518530504000_13.5.e070693.56","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000287431.88658.8b"},{"key":"2025120518530504000_13.5.e070693.57","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-11-356","article-title":"The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?","volume":"11","author":"Gissl\u00e9n","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2025120518530504000_13.5.e070693.58","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab366"},{"key":"2025120518530504000_13.5.e070693.59","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32828e4e27"},{"key":"2025120518530504000_13.5.e070693.60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157160","article-title":"Increased intrathecal immune activation in virally suppressed HIV-1 infected patients with neurocognitive impairment","volume":"11","author":"Ed\u00e9n","year":"2016","journal-title":"PLoS One"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-070693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T02:53:19Z","timestamp":1764989599000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-070693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1136\/bmjopen-2022-070693"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-070693","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}